Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

53.93 -1.96 (-3.51%)
Streaming Delayed Price Updated: 12:32 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 20, 2025 ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Preview Of Travere Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) ↗
 
Via Benzinga
News headline image
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug ↗
The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter. 
Via Stocktwits
News headline image
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug ↗
The company is nearing a highly anticipated approval for a kidney disease drug. 
Via Investor's Business Daily
News headline image
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs ↗
 
Via Benzinga
News headline image
Travere Therapeutics Provides Corporate Update and 2025 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Healthcare Companies
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains. 
Via MarketBeat
News headline image
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' ↗
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker. 
Via Benzinga
News headline image
Travere Therapeutics to Report Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>